Human TNF-α ELISpot Set
Product Specifications
- Catalogue N°
- 856.041.001 - 1 x 96 Discovery (plate not included)
856.041.001P - 1 x 96 Discovery (non-sterile plate)
856.041.001S - 1 x 96 Discovery (sterile plate)
856.041.005 - 5 x 96 (plates not included)
856.041.005P - 5 x 96 (non-sterile plates)
856.041.005S - 5 x 96 (sterile plates)
856.041.010 - 10 x 96 (plates not included)
856.041.010P - 10 x 96 (non-sterile plates)
856.041.010S - 10 x 96 (sterile plates)
856.041.015 - 15 x 96 (plates not included)
856.041.015P - 15 x 96 (non-sterile plates)
856.041.015S - 15 x 96 (sterile plates)
856.041.020 - 20 x 96 (plates not included)
856.041.020P - 20 x 96 (non-sterile plates)
856.041.020S - 20 x 96 (sterile plates) - Target species
- Human
- Specificity
- Recognizes natural human TNF-a
- Incubation
- 3h after cell stimulation
- Cross Reaction
- No cross reactivity with other human cytokines. Cross reacivity with macac TNF-a. No interference with TNFR I and TNFR II.
- Kit Content
- Diaclone ELISpot Sets include capture and detection antibodies, Streptavidin - Alkaline Phosphatase conjugated, BSA, BCIP/NTB and blocking reagent.
- Additional Information
- Spots read visually or with reader
- Synonym
- TNF-a
- TNF-alpha
References
- Godard B. et al., Hum. Immunol., 2004; 65(11): 1307-18 - Pubmed link
- Hudak, S. et al., J Immunol.,2002;169(3): 1189-96. - Pubmed link
- Kalogerakou, F. et al.,Hippokratia,2008; 12(4): 230-5. - Pubmed link
- Kroemer, M. et al., Front Public Health. 2022; 10: 816848. - Pubmed link
Related products
- 855.150.000 - Anti-Human TNF-α Azide Free
- 855.161.019 - Anti-Human TNF-α FITC Conjugated
- 855.162.019 - Anti-Human TNF-α PE Conjugated
- 879.090.001 - Anti-Human TNF-α Capture Antibody
- 879.090.002 - Anti-Human TNF-α Detection Antibody
- 860.040.048 - Murine TNF-α ELISA Kit
- 865.000.048 - Rat TNF-α ELISA Kit
- 950.090.048 - Human TNF-α ELISA Kit
- 851.570.001 - Human TNF-α ELISA Set
- 872.010.001 - Rat TNF-α ELISA Set
- 856.041.001PC - Human TNF-α ELISpot Kit
- 867.021.001 - Rat TNF-α ELISpot Set
- 867.021.001PC - Rat TNF-α ELISpot Kit
- 869.050.010 - Human TNF-α ELISpot Pair
- 871.030.010 - Rat TNF-α ELISpot Pair
- 855.330.000 - Anti-Human TNF-α Azide Free
BACKGROUND
Tumor Necrosis Factor (TNFa), also known as cachectin, is a polypeptide cytokine produced by monocytes and macrophages. It functions as a multipotent modulator of immune response and further acts as a potent pyrogen. TNFa circulates throughout the body responding to stimuli (infectious agents or tissue injury), activating neutrophils, altering the properties of vascular endothelial cells, regulating metabolic activities of other tissues, as well as exhibiting tumoricidal activity by inducing localized blood clotting. TNFa also inhibits lipoprotein lipase activity resulting in cachexia, a physical wasting condition. Activation of B-cells by the Epstein Barr virus can be inhibited by TNFa. Due to its varied actions throughout the immune system, TNFa may play a role in the pathogenesis of many disease states.
TNFa production is mediated by the action of lymphokines and endotoxins on the macrophage. Purified monocytes produce TNFa within four hours of stimulation by recombinant IL-2 and there is some in vitro evidence to suggest that TNFa is expressed at high levels and with prolonged kinetics in T cells stimulated by both CD2 and CD28. Secretion of TNFa is enhanced by gamma interferon. TNFa then induces or enhances the specific production of Class I MHC antigen, GM-CSF, and IL-1. Recent evidence has suggested an intracellular role for this peptide.
TNFa may play a significant role in the pathogenesis of inflammatory disease of the joints and other tissues. Chin et al.found that TNFa, along with IFNg and IL-1 increased cell surface expression of ICAM-1 on synovial fibroblasts. Alvaro-Garcia et al. reported that TNFa stimulates synovial proliferation.
Waage et al. found that increased levels of TNFa in patients with septicemia and meningococcal disease correlated with fatal outcome. Scuderi et al.suggest that increased levels of this cytokine may play a role in the host defense mechanism against parasitic infections. Girardin et al. reported that increased serum TNFa levels correlated with the number of risk factors involved in children with gram-negative sepsis and purpura fulminians. Elevated levels of TNFa were also found in individuals suffering from myocarditis.
Role for TNFa in the pathogenesis of AIDS has also been pointed out. Alveolar macrophages (AM) from HIV positive individuals with opportunistic lung infections have been shown to spontaneously produce higher levels of TNFa in vitro than those HIV positive individuals without infection and HIV negative controls. Krishnan et al.report that higher TNFa production by AM was associated with lower counts of pneumocystis carinii in broncheoalveolar lavage fluid, indicating that TNFa may play a role in the control of this infection in AIDS. Israel-Biet et al.also reported in in vitro studies, that AM that express HIV (p24+) released significantly higher levels of TNFa than p24- alveolar macrophages and controls. Reddy et al.found persistently elevated levels of circulating TNFa in HIV seropositive individuals and suggest a possible involvement of this cytokine in the development of AIDS.
Measurement of TNFa levels has also been shown to be useful in transplant research, where Maury et al.and McLaughlin et al. Both reported TNFa to be markedly elevated in renal allograft rejection episodes. Recent evidence has been presented on increased TNFa levels in Bone Marrow Transplant (BMT). BMT patients with major transplant related complications such as interstitial pneumonitis and severe acute graft-versus - host disease had TNFa levels significantly increase over controls.
Version 10 - 09.22
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.